Arundic Acid

Synonyms: ONO-2506; (R)-2-Propyloctanoic acid
Arundic Acid 是一种口服有效的星形胶质细胞功能调节剂和神经保护剂,它通过激活 ERK、Akt 和 NF-κB 通路增加星形细胞谷氨酸转运体 EAAT1 的表达和功能,在正常眼压性青光眼模型中可减轻视网膜神经节细胞的死亡,在帕金森病小鼠模型中发挥神经保护作用,作为一种 S100β 蛋白合成抑制剂能预防大鼠脑出血后的神经功能缺损和脑组织损伤,并可下调幼鼠癫痫持续状态后的神经炎症和星形胶质细胞功能障碍,可用于帕金森病、脑缺血、青光眼、脑出血及癫痫的相关研究。
产品编号: MS-B59549 纯度: 98.0% CAS No.: 185517-21-9 分子式: C11H22O2 分子量: 186.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Arundic Acid 是一种口服有效的星形胶质细胞功能调节剂和神经保护剂,它通过激活 ERK、Akt 和 NF-κB 通路增加星形细胞谷氨酸转运体 EAAT1 的表达和功能,在正常眼压性青光眼模型中可减轻视网膜神经节细胞的死亡,在帕金森病小鼠模型中发挥神经保护作用,作为一种 S100β 蛋白合成抑制剂能预防大鼠脑出血后的神经功能缺损和脑组织损伤,并可下调幼鼠癫痫持续状态后的神经炎症和星形胶质细胞功能障碍,可用于帕金森病、脑缺血、青光眼、脑出血及癫痫的相关研究。

生物实验数据

生物活性 Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent that increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt, and NF-κB pathways, attenuates retinal ganglion cell death in a normal-tension glaucoma model, exerts neuroprotective effects in a mouse model of Parkinson's disease, prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats as an S100β protein synthesis inhibitor, downregulates neuroinflammation and astrocyte dysfunction after status epilepticus in young rats, and can be used for research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage, and epilepsy.
体外研究
(In Vitro)

Arundic acid (0-100 μM; 3-24 h) 可增强人星形胶质细胞 H4 细胞中 EAAT1/EAAT2 启动子的活性。
Arundic acid (6.25-100 μM; 24 h) 通过 Akt、ERK 和 NF-κB 通路介导人星形胶质细胞 H4 细胞中 EAAT1 启动子活性、mRNA、蛋白水平及谷氨酸摄取功能的上调。
Arundic acid (50 μM; 3-24 h) 可通过降低细胞质中 IκBα 水平并诱导 NF-κB p65 的核转位,在人星形胶质细胞 H4 中激活 NF-κB 通路。
Arundic acid (50 μM; 5 min-24 h) 可在处理后 5 min 内激活 Akt 和 ERK 信号通路。
Arundic acid (50 μM; 24 h) 可通过抑制人星形胶质细胞 H4 中被 Mn 激活的 YY1 表达,缓解 Mn 诱导的 EAAT1 表达抑制。
Arundic acid (100 μM; 14 days) 可通过提高 Vmax、不改变谷氨酸亲和力的方式,增强原代培养小鼠 Müller 细胞的谷氨酸摄取速率。
Arundic acid (0-100 μM; 14 days) 可上调原代培养小鼠 Müller 细胞中 GLAST mRNA 的表达。
Arundic acid 可调节培养大鼠大脑星形胶质细胞中的多种星形胶质细胞活化反应,包括抑制 S-100β 上调及促炎基因表达,且不会改变 GFAP 水平。

Real Time qPCR

Cell Line: Primary cultured mouse Müller cells
Concentration: 0, 12.5, 25, 50, 100 μM
Incubation Time: 14 days
Result: Increased endogenous GLAST mRNA expression.
Detected GLAST mRNA induction as early as 24 h post-treatment.

Western Blot Analysis

Cell Line: human astrocyte H4
cell
Concentration: 0, 6.25, 12.5, 25, 50, 100 μM
Incubation Time: 24 h
Result: Increased EAAT1 protein expression.

Western Blot Analysis

Cell Line: human astrocyte H4
cell
Concentration: 50 μM
Incubation Time: 0, 6, 12, 24 h
Result: Enhanced NF-κB reporter gene activity and reduced IκBα levels in cytoplasmic components
体内研究
(In Vivo)

Arundic acid (10 mg/kg; p.o.; daily; 14 days) 可在患有正常眼压性青光眼样变性的 GLAST 杂合子小鼠中上调视网膜 GLAST 表达、增强谷氨酸摄取,并使视网膜神经节细胞计数增加约 19.7%。
Arundic acid (30 mg/kg; i.p.; 5 post-MPTP doses) 在 MPTP (MS-O89430) 帕金森病小鼠模型中可保护小鼠多巴胺能神经元免受 MPTP 的神经毒性作用,维持纹状体 52%的多巴胺水平、黑质 44%的多巴胺能神经元,并改善运动功能缺陷。
Arundic acid (0.02-20 μg/μL; i.c.v.; single dose) 可降低健康雄性 Wistar 大鼠纹状体中的 S100B 和 GFAP 水平。
Arundic acid (2 μg/μL; i.c.v.; single dose;) 可逆转雄性 Wistar 大鼠中 ICH 诱导的神经功能缺损,减小纹状体损伤体积,抑制反应性星形胶质细胞增生,阻止神经元凋亡,使中枢和外周 S100B 水平恢复正常,并增强早期抗氧化防御能力。
Arundic acid (10 mg/kg; i.p.; single injection; 6 h or 24 h post-SE induction) 可通过减轻海马神经炎症、逆转星形胶质细胞功能障碍、恢复谷氨酸稳态并改善葡萄糖摄取,对锂-匹鲁卡品诱导癫痫持续状态 (SE) 的大鼠发挥神经保护作用,其中 SE 诱导后 24 h 给药在各终点指标上显示出更稳定的疗效。

Animal Model: C57BL/6J (backcrossed for ≥10 generations; GLAST heterozygous; postnatal day 22 to 35)
Dosage: 10 mg/kg
Administration: p.o.; daily; 14 days
Result: Increased retinal GLAST mRNA levels relative to vehicle controls.
Increased retinal GLAST protein expression relative to vehicle controls.
Increased retinal glutamate uptake velocity by 1.23-fold relative to vehicle-treated GLAST+/- mice.
Increased GCL neuron count to 438 cells per retina, compared with 366 cells in vehicle-treated GLAST+/- mice.
Showed no effect on glutamate uptake in GLAST-/- mice.
Animal Model: C57BL/6 (male, 10 weeks old, 22-28 g, MPTP-induced Parkinson’s disease)
Dosage: 30 mg/kg
Administration: i.p.; 5 doses at 1 minute, 6 h, 24 h, 48 h, 72 h after last MPTP injection
Result: Preserved striatal dopamine levels at 52% of normal control values.
Preserved striatal DOPAC and HVA levels at 47% and 60% of normal control values, respectively.
Significantly reduced motor function deficits in the pole test (T-turn and T-LA) and catalepsy test.
Preserved the number of tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra pars compacta at 42% of normal control values 3 days after MPTP injection and 44% of normal control values 7 days after MPTP injection.
Induced earlier appearance of GFAP-positive reactive astrocytes (by 3 days post-MPTP) compared to MPTP-only mice, with GFAP immunoreactivity comparable to MPTP-only mice at 7 days.
Reduced S-100 immunoreactivity in the substantia nigra at 3 days and in the striatum at 7 days post-MPTP compared to MPTP-only mice.
Showed no significant effect on microglial activation relative to MPTP-only mice.
Animal Model: Wistar rats (adult male, 90 days-old, 300-350 g)
Dosage: 0.02 μg/μL; 0.2 μg/μL; 2 μg/μL; 20 μg/μL
Administration: i.c.v.; single dose
Result: Significantly reduced striatal S100B immunocontent at 0.2 μg/μL and 2 μg/μL doses compared to control groups.
Significantly reduced striatal GFAP immunocontent at 2 μg/μL dose compared to control groups.
Showed no inhibitory effect on either S100B or GFAP levels at 20 μg/μL dose.
Animal Model: Wistar rats (adult male, 90 days-old, 300-350 g, intracerebral hemorrhage induced by intrastriatal injection of type-IV collagenase)
Dosage: 2 μg/μL
Administration: i.c.v.; single dose; administered immediately before ICH induction
Result: Reversed motor dysfunction completely at 7 days post-injury, with neurological scores and significantly.
Reduced striatal lesion volume significantly at 7 days post-injury.
Lowered striatal GFAP and S100B fluorescence intensity and immunostained surface area significantly at 7 days post-injury.
Increased NeuN fluorescence intensity and number of NeuN-positive cells significantly at 7 days post-injury.
Decreased cleaved caspase-3 fluorescence intensity and number of cleaved caspase-3-positive cells significantly at 7 days post-injury.
Lowered striatal GFAP levels significantly at 7 days post-injury.
Lowered striatal S100B levels significantly at 7 days post-injury; lowered cerebrospinal fluid S100B levels significantly at 72 hours post-injury; lowered serum S100B levels significantly at 24 hours and 7 days post-injury.
Increased striatal GSH levels significantly at 24 hours post-injury.
Decreased striatal GS activity significantly at 24 hours post-injury.
Animal Model: Wistar rats (male, postnatal day 27)
Dosage: 10 mg/kg (6 h post-SE induction); 10 mg/kg (24 h post-SE induction)
Administration: i.p.; single injection
Result: Partially reversed elevated hippocampal IL-1β levels, abolished elevated hippocampal TLR4 protein expression, partially reversed elevated hippocampal COX2 protein expression, increased hippocampal TGF-β levels, and did not alter TNF-α, RAGE, or Iba1 levels at 6 h post-SE.
Prevented elevated hippocampal IL-1β levels, decreased hippocampal TNF-α levels, prevented elevated hippocampal RAGE and TLR4 protein expression, completely abolished elevated hippocampal COX2 protein expression, partially reversed elevated hippocampal Iba1 levels, and increased hippocampal TGF-β levels at 24 h post-SE.
Prevented elevated hippocampal GFAP levels at 6 h and 24 h post-SE.
Partially reversed elevated hippocampal S100B levels, reversed reduced hippocampal connexin-43 (Cx-43) protein expression, partially reversed elevated CSF S100B levels, and partially reversed reduced serum S100B levels at 6 h post-SE.
Abolished elevated hippocampal S100B levels, and did not alter reduced hippocampal Cx-43 levels or CSF/serum S100B levels at 24 h post-SE.
Reversed reduced hippocampal GLAST protein expression, partially reversed reduced hippocampal GLT1 protein expression, reversed increased hippocampal glutamate uptake, did not alter reduced hippocampal GSH levels, partially reversed reduced hippocampal glutamine synthetase (GS) activity, and reversed reduced hippocampal GS protein expression at 6 h post-SE.
Partially reversed reduced hippocampal GLAST protein expression, partially reversed reduced hippocampal GLT1 protein expression, reversed increased hippocampal glutamate uptake, prevented reduced hippocampal GSH levels, did not alter reduced hippocampal GS activity, and reversed reduced hippocampal GS protein expression at 24 h post-SE.
Abolished reduced hippocampal glucose uptake, and did not alter hippocampal GLUT1 protein expression at 6 h and 24 h post-SE.
性状 液体(密度:0.908 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 186.29
分子式 C11H22O2
CAS No. 185517-21-9
别名 ONO-2506; (R)-2-Propyloctanoic acid

储存&溶解度

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (536.80 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.3680 mL26.8399 mL53.6797 mL134.1994 mL
5 mM1.0736 mL5.3680 mL10.7359 mL26.8399 mL
10 mM0.5368 mL2.6840 mL5.3680 mL13.4199 mL
15 mM0.3579 mL1.7893 mL3.5786 mL8.9466 mL
20 mM0.2684 mL1.3420 mL2.6840 mL6.7100 mL
25 mM0.2147 mL1.0736 mL2.1472 mL5.3680 mL
30 mM0.1789 mL0.8947 mL1.7893 mL4.4733 mL
40 mM0.1342 mL0.6710 mL1.3420 mL3.3550 mL
50 mM0.1074 mL0.5368 mL1.0736 mL2.6840 mL
60 mM0.0895 mL0.4473 mL0.8947 mL2.2367 mL
80 mM0.0671 mL0.3355 mL0.6710 mL1.6775 mL
100 mM0.0537 mL0.2684 mL0.5368 mL1.3420 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础